Guardant Health Inc (GH)
Guardant Health, Inc. - Guardant Health Receives FDA Approval forGuardant360® CDx as a Companion Diagnostic for Arvinas andPfizer’s VEPPANU (vepdegestrant) for Patients with ER+/HER2- Advanced Breast Cancer with ESR1 Mutations
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (95%) **Content type:** Clinical